287 related articles for article (PubMed ID: 25241899)
1. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
[TBL] [Abstract][Full Text] [Related]
2. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
Cittelly DM; Finlay-Schultz J; Howe EN; Spoelstra NS; Axlund SD; Hendricks P; Jacobsen BM; Sartorius CA; Richer JK
Oncogene; 2013 May; 32(20):2555-64. PubMed ID: 22751119
[TBL] [Abstract][Full Text] [Related]
3. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
4. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
[TBL] [Abstract][Full Text] [Related]
5. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
[TBL] [Abstract][Full Text] [Related]
6. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
8. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
9. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
Subtil-Rodríguez A; Millán-Ariño L; Quiles I; Ballaré C; Beato M; Jordan A
Mol Cell Biol; 2008 Jun; 28(11):3830-49. PubMed ID: 18378698
[TBL] [Abstract][Full Text] [Related]
10. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract][Full Text] [Related]
11. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
[TBL] [Abstract][Full Text] [Related]
12. miR-129-2 mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells.
Godbole M; Chandrani P; Gardi N; Dhamne H; Patel K; Yadav N; Gupta S; Badwe R; Dutt A
Cancer Biol Ther; 2017 Oct; 18(10):801-805. PubMed ID: 28876975
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells.
Obr AE; Grimm SL; Bishop KA; Pike JW; Lydon JP; Edwards DP
Mol Endocrinol; 2013 Nov; 27(11):1808-24. PubMed ID: 24014651
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
[TBL] [Abstract][Full Text] [Related]
16. Loss of miR-6844 alters stemness/self-renewal and cancer hallmark(s) markers through CD44-JAK2-STAT3 signaling axis in breast cancer stem-like cells.
Prajapati KS; Kumar S
J Cell Biochem; 2023 Aug; 124(8):1186-1202. PubMed ID: 37436061
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
[TBL] [Abstract][Full Text] [Related]
18. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.
Liu R; Zhou Z; Zhao D; Chen C
Mol Endocrinol; 2011 Jul; 25(7):1137-44. PubMed ID: 21566082
[TBL] [Abstract][Full Text] [Related]
19. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
Tran TH; Utama FE; Lin J; Yang N; Sjolund AB; Ryder A; Johnson KJ; Neilson LM; Liu C; Brill KL; Rosenberg AL; Witkiewicz AK; Rui H
Cancer Res; 2010 Feb; 70(4):1711-21. PubMed ID: 20124477
[TBL] [Abstract][Full Text] [Related]
20. miR-221/222 control luminal breast cancer tumor progression by regulating different targets.
Dentelli P; Traversa M; Rosso A; Togliatto G; Olgasi C; Marchiò C; Provero P; Lembo A; Bon G; Annaratone L; Sapino A; Falcioni R; Brizzi MF
Cell Cycle; 2014; 13(11):1811-26. PubMed ID: 24736554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
